NURS 5334 FINAL PAPER TEST BANK EXAM Q&A 2026 100% CORRECT

NURS 5334 FINAL PAPER TEST BANK EXAM
Q&A 2026 100% CORRECT.

⫸ Tretinoin. Answer: Normalizes keratinization, anti-inflammatory


⫸ Comedonal/mild acne. Answer: Indications for tretinoin


⫸ Severe/nodular acne. Answer: Indications for isotretinoin


⫸ Mild acne (no inflammation). Answer: Indications for benzoyl
peroxide


⫸ Clindamycin / Erythromycin (topical). Answer: Inhibits bacterial
protein synthesis


⫸ Inflammatory acne. Answer: Indications for
clindamycin/erythromycin


⫸ Azelaic Acid. Answer: Antibacterial, anti-inflammatory


⫸ Mild-moderate acne, rosacea. Answer: Indications for azelaic acid


⫸ Metronidazole (topical). Answer: Antimicrobial, anti-
inflammatory

,⫸ Rosacea. Answer: Indications for metronidazole


⫸ Doxycycline (oral). Answer: Inhibits protein synthesis


⫸ Moderate rosacea. Answer: Indications for doxycycline


⫸ 5-Fluorouracil (Efudex). Answer: Inhibits DNA/RNA synthesis


⫸ Precancerous lesions. Answer: Indications for 5-fluorouracil


⫸ Imiquimod (Aldara). Answer: Immune modulator (↑ cytokines)


⫸ Actinic keratosis, warts. Answer: Indications for imiquimod


⫸ Hydrocortisone / Triamcinolone (topical steroids). Answer: ↓
Inflammation via cytokine suppression


⫸ Atopic dermatitis, eczema. Answer: Indications for
hydrocortisone/triamcinolone


⫸ Tacrolimus (Protopic). Answer: Calcineurin inhibitor → ↓ T-cell
activation

,⫸ Chronic eczema, steroid-sparing. Answer: Indications for
tacrolimus


⫸ Tazarotene (Tazorac). Answer: Retinoid; normalizes keratinocytes


⫸ Plaque psoriasis. Answer: Indications for tazarotene


⫸ Calcipotriene (Dovonex). Answer: Vitamin D analogue → ↓
keratinocytes


⫸ Methotrexate. Answer: Folate antagonist → ↓ DNA synthesis


⫸ Severe psoriasis, arthritis. Answer: Indications for methotrexate


⫸ Pharmacodynamics (PD). Answer: Vaccines present antigen (live-
attenuated or inactivated/subunit) → APC uptake → T-cell priming →
B-cell maturation → neutralizing IgG (±mucosal IgA) and memory.


⫸ Live vaccines. Answer: Typically produce broader/longer
immunity than inactivated.


⫸ Re-immunization. Answer: Safe; reduced doses should not be
used.

, ⫸ Major absolute contraindication. Answer: Prior anaphylaxis to a
dose/component.


⫸ Pharmacokinetics (PK). Answer: No classical
absorption/distribution/elimination like small molecules. Antigen
remains largely local/intramuscular/intradermal, drains to regional
lymphatics; immune effect persists via memory cells (months-years).


⫸ Key interactions. Answer: IVIG/IG interferes with live vaccines
(e.g., MMR, varicella)—separate per ACIP timing; space live-virus
vaccines; most inactivated vaccines can be co-administered at
different sites.


⫸ Varicella. Answer: Routine childhood 2-dose series; susceptible
adults.


⫸ Zoster (RZV, Shingrix). Answer: ≥50 y (2 doses, 2-6 mo apart) for
shingles & post-herpetic neuralgia prevention.


⫸ ADEs for Varicella. Answer: Local pain/erythema; occasional
mild varicella-like rash (live).


⫸ ADEs for RZV. Answer: Injection-site pain, fever, myalgias.


⫸ Contraindications for Varicella. Answer: Live varicella
contraindicated in pregnancy and severe immunocompromise; defer
during active moderate/severe illness.